BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent(TM) Technology

27-May-2005

BioWa, Inc. and Medarex, Inc. announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of antibody-dependent cellular cytotoxicity (ADCC). Medarex plans to use the Potelligent Technology to enhance the ADCC function of selected Medarex antibodies for potential therapeutic applications, including cancer. The agreement provides Medarex with nonexclusive commercial rights to develop antibodies for an undisclosed number of targets. In return, BioWa will receive license fees, and could receive milestone payments and royalties on products developed by Medarex. Detailed licensing terms/financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous